RetractedArticleiScience2023

SMYD3 induces sorafenib resistance by activating SMAD2/3-mediated epithelial-mesenchymal transition in hepatocellular carcinoma.

Shanshan Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.